US4725272A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel bandage for administering beneficial drug
Assignee: Alza Corp
•
Filing: 1981-06-29
•
Granted: 1988-02-16
•
Expires: 2001-06-29
Abstract
Abstract A medical bandage is disclosed comprising a reservoir containing a gelled fluid, rheological agent and a drug. A method of using the bandage for producing a beneficial effect is disclosed also.
Inventors
- 👤 Robert M. Gale
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:43
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
167 words
A method for treating angina pectoris in a human, which method comprises: (a) placing on the skin of a human afflicted with angina pectoris a medical bandage comprising: (1) a backing member that is substantially impermeable to the passage of a drug, one face of which forms the top of the bandage; (2) a reservoir adjacent to the opposite face of the backing member, the reservoir comprising gelled silicone fluid, silicon dioxide, and a vasodilator having a group selected from the group consisting of ONO and ONO 2 useful for treating angina pectoris; (3) a rate controlling membrane adjacent and below the reservoir, which membrane is permeable to the passage of the vasodilator, controls its rate of release from the bandage and is in contact with the backing member to form a substantially fluid-tight medical bandage; and, (4) a contact adhesive for holding the medical bandage on the skin; and, (b) administering the vasodilator to the skin in a therapeutically effective amount for treating said angina pectoris.
Claim 2
Independent Claim
167 words
A method for treating angina pectoris in a human, which method comprises: (a) placing on the skin of a human afflicted with angina pectoris a medical bandage comprising: (1) a backing member that is substantially impermeable to the passage of a drug, one face of which forms the top of the bandage; (2) a reservoir adjacent to the opposite face of the backing member, the reservoir comprising gelled silicone fluid, silicon dioxide, and a vasodilator having a group selected from the group consisting of ONO and ONO 2 useful for treating angina pectoris; (3) a rate controlling membrane adjacent and below the reservoir, which membrane is permeable to the passage of the vasodilator, controls its rate of release from the bandage and is in contact with the backing member to form a substantially fluid-tight medical bandage; and, (4) a contact adhesive for holding the medical bandage on the skin; and, (b) administering the vasodilator to the skin in a therapeutically effective amount for treating said angina pectoris.
Claim 3
Dependent Claim
29 words
The method for treating angina pectoris according to claim 1, wherein the contact adhesive is adjacent and below the rate controlling membrane for holding the bandage on the skin.
Claim 4
Dependent Claim
26 words
The method for treating angina pectoris according to claim 1, wherein the vasodilator is administered in a therapeutically effective primary dose for treating said angina pectoris.
Claim 5
Dependent Claim
45 words
The method for treating angina pectoris according to claim 1 wherein the backing member is a laminate comprising a lamina of polyethylene in laminar arrangement with a lamina of aluminized polyethylene-terephthalate and a lamina of ethylene-vinyl acetate copolymer, which copolymer is adjacent to said reservoir.
Claim 6
Dependent Claim
42 words
The method for treating angina pectoris according to claim 1, wherein the backing member is a laminate comprising a lamina of aluminizied polyethylene-terephthalate, a lamina of an ionomer, and a lamina of ethylene-vinyl acetate copolymer, which copolymer is adjacent to the reservoir.
Claim 7
Dependent Claim
19 words
The method for treating angina pectoris according to claim 1 wherein the rate controlling membrane is ethylene-vinyl acetate copolymer.
Claim 8
Dependent Claim
18 words
The method for treating angina pectoris according to claim 1, wherein the vasolidator in the reservoir is nitroglycerin.
Claim 9
Dependent Claim
25 words
The method for treating angina pectoris according to claim 1, wherein during a 24 hour period more than one bandage is placed on the skin.
Claim 10
Dependent Claim
23 words
The method for treating angina pectoris according to claim 1 wherein more than one bandage is on the skin at the same time.
Claim 11
Dependent Claim
49 words
The method for treating angina pectoris according to claim 1, wherein the contact adhesive is replaced by a lamina comprising an adhesive and a protective liner is adjacent to the rate controlling membrane and the liner is pulled from the bandage before said bandage is placed on the skin.
Claim 12
Dependent Claim
37 words
The method for treating angina pectoris according to claim 1, wherein the contact adhesive is replaced by mechanical means for holding the bandage on the skin, and the rate controlling membrane is in contact with the skin.
Claim 13
Dependent Claim
22 words
The method for treating angina pectoris according to claim 1, wherein rate controlling membrane is copolymer of tetramethylene terephthalate-polytetramethylene ether glycol terephthalate.
Claim 14
Dependent Claim
55 words
The method for treating angina pectoris according to claim 1, wherein the backing member is a laminate comprising a lamina of polyethylene in laminar arrangement with a lamina of aluminized polyethylene-terephthalate and a lamina of ethylene-vinyl acetate copolymer, the reservoir comprises gelled silicone fluid, silicon dioxide, and the rate controlling membrane is ethylene-vinyl acetate copolymer.
Claim 15
Dependent Claim
59 words
The method for treating angina pectoris according to claim 1, wherein the backing member is a laminate comprising a lamina of aluminized polyethylene-terephthalate, a lamina of ionomer, and a lamina of ethylene-vinyl acetate copolymer, the reservoir comprises gelled silicone fluid, silicon dioxide, and a dosage amount of the vasodilator nitroglycerin, and the rate controlling membrane is ethylene-vinyl acetate copolymer.
Claim 16
Dependent Claim
136 words
A therapeutic system in the form of a bandage for administering a drug, the system comprising: (a) a backing member that is substantially impermeable to the passage of drug, one surface of which defines the top of the system; (b) a reservoir adjacent to the opposite surface of the backing member, the reservoir comprising gelled silicone fluid, silicone dioxide, and a dosage unit amount of a vasodilator drug formulation comprising a member selected from the group consisting of ONO and ONO 2 ; (c) a membrane adjacent to and below the reservoir, the membrane comprising a composition that controls the rate of release of the drug from the system, and is in contact with the backing member to form a substantially fluid-tight system; and, (d) a contact adhesive means for holding the bandage on a recipient.
Claim 17
Dependent Claim
136 words
A therapeutic system in the form of a bandage for administering a drug, the system comprising: (a) a backing member that is substantially impermeable to the passage of drug, one surface of which defines the top of the system; (b) a reservoir adjacent to the opposite surface of the backing member, the reservoir comprising gelled silicone fluid, silicone dioxide, and a dosage unit amount of a vasodilator drug formulation comprising a member selected from the group consisting of ONO and ONO 2 ; (c) a membrane adjacent to and below the reservoir, the membrane comprising a composition that controls the rate of release of the drug from the system, and is in contact with the backing member to form a substantially fluid-tight system; and, (d) a contact adhesive means for holding the bandage on a recipient.
Claim 18
Dependent Claim
40 words
The therapeutic system in the form of a bandage according to claim 15, wherein the system is adapted for administering the drug to an animal, and the adhesive is replaced by mechanical means for holding the system on the animal.
Claim 19
Dependent Claim
74 words
The therapeutic system in the form of a bandage according to claim 15, wherein the system is adapted for administering the drug to an animal, the adhesive is in contact with the rate controlling membrane and a lamina is adjacent and below the adhesive, which lamina is substantially impermeable to the passage of a drug present in the system and is adapted to be stripped therefrom before the system is affixed to the animal.
Claim 20
Dependent Claim
39 words
The therapeutic system in the form of a bandage according to claim 15 wherein the backing member comprises a lamina of polyethylene laminated to a lamina of aluminized polyethylene-terephthalate which is laminated to a lamina of ethylene-vinyl acetate copolymer.
Claim 21
Dependent Claim
37 words
The therapeutic system in the form of a bandage according to claim 15 wherein the backing member comprises a lamina of aluminized polyethylene-terephthalate laminated to an ionomer which is laminated to a lamina of ethylene-vinyl acetate copolymer.
Claim 22
Dependent Claim
22 words
The therapeutic system in the form of a bandage according to claim 15 wherein the rate controlling membrane is ethylene-vinyl acetate copolymer.
Claim 23
Dependent Claim
25 words
The therapeutic system in the form of a bandage according to claim 15 wherein the drug formulation in the reservoir is nitroglycerin absorbed on lactose.
Claim 24
Dependent Claim
50 words
The therapeutic system in the form of a bandage according to claim 15, wherein the rate controlling membrane is ethylene-vinyl acetate copolymer having a vinyl acetate content of 9 wt%, the vasodilator is nitroglycerin, and it is administered in the therapeutically effective amount of about 10 μg/hr to 1200 μg/hr.
Claim 25
Dependent Claim
35 words
The therapeutic system in the form of a bandage according to claim 15 wherein the reservoir contains from 5 mg to 1000 mg of the vasodilator nitroglycerin, the rate controlling membrane is ethylene-vinyl acetate copolymer.
Claim 26
Dependent Claim
88 words
The therapeutic system in the form of a bandage according to claim 15 wherein the backing member comprises a lamina of polyethylene in laminar arrangement with a lamina of aluminized polyethylene-terephthalate and a lamina of ethylene-vinyl acetate copolymer; the reservoir comprises gelled silicone fluid, silicon dioxide, and a dosage amount of the vasodilator nitroglycerin; the membrane that controls the rate of release is ethylene-vinyl acetate copolymer; and the system comprises an adhesive in contact with the membrane and a lamina of kraft paper, in contact with the adhesive.
Claim 27
Dependent Claim
84 words
The therapeutic system in the form of a bandage according to claim 15 wherein the backing member comprises a lamina of aluminized polyethylene-terephthalate, a lamina of ionomer, and a lamina of ethylene-vinyl acetate copolymer; the reservoir comprises gelled silicone fluid, silicon dioxide, and a dosage amount of the vasodilator nitroglycerin; the membrane that controls the rate of release is ethylene-vinyl acetate copolymer; and the system comprises an adhesive in contact with the membrane and a lamina of polyvinyl chloride in contact with the adhesive.
Claim 28
Dependent Claim
23 words
The therapeutic system in the form of a bandage for administering the drug according to claim 15, wherein the drug is isosorbide dinitrate.
Claim 29
Dependent Claim
27 words
The therapeutic system in the form of a bandage for administering the drug according to claim 15, wherein the therapeutic system releases an initial pulse of drug.
Claim 30
Dependent Claim
39 words
The therapeutic system in the form of a bandage for administering the drug according to claim 15, wherein the therapeutic system releases an initial priming dose of drug and thereafter the system delivers drug at a substantially constant rate.
Claim 31
Dependent Claim
43 words
The therapeutic system in the form of a bandage for administering the drug according to claim 15, wherein the system comprises an adhesive in contact with the rate controlling membrane, and the adhesive contains a drug that is released as a priming dose.
References Cited (Backward Citations)
US3797494A
Cited
US3948262A
Cited
US3742951B1
Cited
US3996934A
Cited
US3742951A
Cited
US3980084A
Cited
US4031894A
Cited
US4262003A
Cited
US4060084A
Cited
US4350785A
Cited
US4286592A
Cited
US4329333A
Cited
US4486193A
Cited
US4650484A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-15 | 1991-08-17 | 1992-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-15 | 1995-08-17 | 1996-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-15 | 1999-08-17 | 2000-02-16 | $7700.00 | Window Closed / Lapsed |